

The Honorable John J. Lawn, House Chair
Joint Committee on Health Care Financing
State House, Room 236
Boston, MA 02133

The Honorable Cindy F. Friedman, Senate
Chair
Joint Committee on Health Care Financing
State House, Room 313
Boston, MA 02133

July 15, 2025

Dear Chair Lawn and Chair Friedman,

On behalf of the thousands of Massachusetts patients and families that our organizations represent, we express our support for S.848, *An Act relating to covered entity reporting to increase accountability to safeguard benefit for vulnerable patients*.

The Federal 340B program was initially designed to increase access to affordable medications for underserved patients by providing discounted pricing for drugs purchased by eligible healthcare entities. At its best, the program allows providers to expand services and improve access to care for vulnerable patients. However, as the program has grown in scale and complexity, there has been little visibility into how savings are used, whether patients directly benefit, or how much is retained by intermediaries like contract pharmacies or third-party administrators. Without clear and consistent reporting requirements, it is difficult to ensure that 340B savings reach the patients the program intended to support.

S.848 offers a thoughtful and necessary step toward improving accountability within the 340B program in Massachusetts. The bill addresses concerns with transparency by requiring covered entities to report detailed, meaningful data on how 340B savings are used, including how discounts are passed on to patients, investments in charity care, and payments to third-party vendors, such as pharmacy benefit managers (PBMs). It will give policymakers, patients, and the public a clearer picture of how 340B savings are used. This level of transparency is essential to ensuring that the program's benefits are directed toward patient care, not administrative overhead or profit.

According to [data from the Pioneer Institute](#), over half of the contract pharmacies meant to serve low-income patients in Massachusetts are situated in wealthy neighborhoods. Additionally, 21% of the 340B pharmacies that claim to serve low-income patients in Massachusetts are located outside of the state.

Safety-net resources must be used effectively, fairly, and in accordance with the public interest. We respectfully request that this committee support S.848, which would strengthen the 340B program, uphold its original mission, and ensure it continues to serve the needs of vulnerable patients across Massachusetts.

Sincerely,

Asthma and Allergy Foundation New England Chapter

CancerCare

Community Liver Alliance

Envisioning Access

Global Healthy Living Foundation

HeartBrothers Foundation

IMPACT Melanoma

Infusion Access Foundation

Lupus Foundation of New England

Massachusetts Association for Mental Health

Massachusetts Pain Initiative

Rare New England